Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in ...

A first-line regimen combining encorafenib, cetuximab, and mFOLFOX6 significantly increases progression-free survival (12.8 vs. 7.1 months) and overall survival (30.3 vs. 15.1 months) compared to ...

Researchers led by Université de Montréal pathology and cell-biology professor Marc Therrien have identified major structural changes that enable the BRAF protein to escape control and mimic its ...

"Fore Bio is focused on resetting the standard in BRAF driven tumors with a potential first in class paradox breaker with compelling early clinical data that support the potential of plixorafenib ...

New Team Science Award is $1.5 million Over Three Years NEW YORK, June 17, 2025 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) announces today a new funding mechanism: the 2025 LCRF Team ...

Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in the body.

No writing assistance was utilized in the production of this manuscript. BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK ...

Article continues below A genetic mutation, BRAF, was detected, which allowed him to begin targeted drug therapy, Dabrafenib and Trametinib - a daily treatment aimed at keeping the cancer at bay.